



Papillary muscle PVC ablation



Yoo Ri Kim

Dongguk University, School of Medicine, Korea





Korean Heart Rhythm Society COI Disclosure

Yoo Ri Kim:

The author is a consultant (receiving consulting fees) of InterMD company and an (unpaid) advisor of Digital Healthcare Partners (DHP)





Content

1. ECG Characteristics & anatomic consideration
2. Differential diagnosis & clinical characteristics
3. Treatment and prognosis
 - 1) Catheter ablation techniques
 - ① With 3D
 - ② With ICE
 - ③ With Cryo
 - 2) Practical aspect of ablation of PM VA
4. Summary





Anatomic consideration







ECG characteristics & Anatomy






Fascicular vs. Papillary m

- no lateral q wave -






Case1. 34/M palpitation



RBBB, superior axis, wider QRS, V1 qR wave, no q in lateral leads



Case2. 54/F neck pounding, presyncope



V1 qR pattern, inferior axis, deep S in V6, lateral no q wave



Clinical characteristics of PM VA

- Inducibility with exertion of epinephrine, isoproterenol
- PVCs rather than VT
- Lack of inducibility with PES (V or A stim)
- Refractoriness to verapamil and Na⁺ channel blocker
- Earliest V activation on the PM
- Challenging to ablate

Ventricular Fibrillation Triggered by PVCs from Papillary Muscles: Clinical Features and Ablation

FRANCESCO SANTORO, M.D.,*† LUIGI DI BIASE, M.D., Ph.D., F.H.R.S.,*†,‡,§
PATRICK HRANITZKY, M.D.,†,¶ JAVIER E. SANCHEZ, M.D.,† PASQUALE SANTANGELI,
M.D.,*† ALESSANDRO PAOLETTI PERINI, M.D.,# JOHN DAVID BURKHARDT, M.D.,
F.H.R.S.,‡ and ANDREA NATALE, M.D., F.H.R.S.†,‡,||,**,††

From the *Department of Cardiology, University of Foggia, Foggia, Italy; †Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, Texas, USA; ‡Department of Biomedical Engineering, University of Texas, Austin, Texas, USA; §Albert Einstein College of Medicine, Montefiore Hospital, New York, USA; ¶Division of Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; #Department of Heart and Vessel, University of Florence, Florence, Italy; ||EP Services, California Pacific Medical Center, San Francisco, California, USA; **Interventional Electrophysiology, Scripps Clinic, San Diego, California, USA; and ††Case Western Reserve University, Cleveland, Ohio, USA

VF from Papillary Muscle. *Background:* Animal studies showed that papillary muscles can be sources of ventricular fibrillation (VF) in both the left and right ventricle, but this occurrence in humans has been described only in patients with ischemic heart disease.

Objective: To investigate the role of papillary muscle premature ventricular contractions (PVCs) as triggers for VF and the safety and feasibility of catheter ablation in these patients.

Methods: Six patients (2 male; age, 40 ± 11 years; 5 with a normal structural heart and 1 with nonischemic cardiomyopathy) with history of VF resulting in repetitive implantable cardioverter defibrillator shocks, despite antiarrhythmic drug therapy, and a papillary muscle focus of PVCs triggering VF were included and underwent mapping and ablation of PVCs.

Results: PVCs were observed to trigger VF and localized by mapping the earliest activation point that matched pace mapping of the same area. In 2 patients, PVCs originated from the left ventricle at the posteromedial papillary muscle; in 4 patients, PVCs originated from the right ventricle, at the posterolateral papillary muscle. Elimination of the triggering PVC was obtained in these areas after 19 ± 12 minutes by radiofrequency application. During a follow-up of 58 ± 11 months using ambulatory monitoring and defibrillator memory interrogation, no patients had recurrence of symptomatic ventricular arrhythmias.


Conclusion: Papillary muscles from both ventricles represent an anatomic structure potentially involved in the onset of VF, also in normal structural heart. PVCs arising from this area can be successfully eliminated by radiofrequency ablation, resulting in freedom from recurrent VF at long-term follow-up. (*J Cardiovasc Electrophysiol*, Vol. 25, pp. 1158-1164, November 2014)



Case2. 42% PVC, no MVP, LVEF 49%

Location: Unknown		Room ID: IM03	
HOLTER REPORT			
General		Heart Rates	
147259	QRS complexes	104	Minimum at 05:06:23 15-Apr
61637	Ventricular beats (42%)	101	Average
0	Supraventricular beats (< 1%)	141	Maximum at 22:27:27 14-Apr
1	% of total time classified as noise	3601	Beats in tachycardia (>100 bpm), 2% total
		0	Beats in bradycardia (<60 bpm), 0% total
		1.16	Seconds Max R-R at 06:08:42 15-Apr
Ventriculars (V, F, E, I)		Supraventriculars (S, J, A)	
46945	Isolated	0	Isolated
5955	Couplets	0	Couplets
39690	Bigeminal cycles	0	Bigeminal cycles
884	Runs totaling 2782 beats	0	Runs totaling 0 beats
6	Beats longest run 140 bpm 22:18:11 14-Apr		
3	Beats fastest run 185 bpm 09:00:30 15-Apr		



VPC Bigeminy



Non-sustained VT (5beats)



Non-sustained VT (5 beats)






Medication

- 4.23, Holter PVC 42%, NSVT 6 beats, presyncope
→ verapamil 40mg tid
- 5.6, Holter PVC 30%, NSVT 5 beats, presyncope
→ verapamil 40mg tid,
→ add propafenone 150mg bid
- 6.2, Holter PVC 31%, LVEF 50% with palpitation
consider **amiodarone** or **catheter ablation**




Baseline PVC ECG



Catheter position


- Duodeca (HRA- distalCS)
- Deca (His-RV)
- Ablation (irrigation DF curve) retrograde aortic approach






EGM at 3D mapping system


His potential




Purkinje potential



Double potential



Fragmented potential





ICE







Fig. 4. (A) Intracardiac ultrasound is performed to assist ablation of arrhythmias rising from left anterolateral papillary muscle. (B, C) It allows clear visualization and confirmation of contact with the anterolateral and posteromedial muscles. ([A] From Liu XK, Barrett R, Packer DL, et al. Successful management of recurrent ventricular tachycardia by electrical isolation of anterolateral papillary muscle. Heart Rhythm 2008;5(3):481; with permission.)

RF ablation





Cryoablation vs. RF ablation




Table 1. Baseline Characteristics

Characteristics	RF (n=9)	CRYO (n=12)	P Value
Age, mean	40.0±10.6	41.4±14.3	0.9
Male	4 (44.4%)	6 (50%)	0.8
LVEF	59.9±9.5	58.1±5.1	0.08
SHD	3 (33.3%)	4 (33.3%)	1.0
VA			
VT	2 (22.2%)	3 (25.0%)	0.04
NSVT	1 (11.1%)	7 (58.3%)	
PVC	6 (66.7%)	2 (16.7%)	
AADs Pre	1 (11.1%)	3 (25%)	0.4
AADs Post	1 (11.1%)	0	0.4

Table 2. Procedural Characteristics


Characteristics	RF (n=9)	CRYO (n=12)	P value
P Success	7 (77.8%)	12 (100.0%)	0.08
Recurrence	4 (44%)	0	0.03
RF Time	11.3±4.2	11.0±3.0	0.9
Energy time	425.3±86.1	700.0±216.1	0.002
TP Time	131.7±9.0	126.5±25.5	0.4
Complications	0	0	...
ProA	8 (88.9%)	0	0.001
Cath Stab	2 (22.2%)	12 (100.0%)	0.001
Days F-UP	87 (IQR, 65–148)	360 (IQR, 116–365)	...

Cath stab indicates catheter stability during energy delivery; CRYO,



Contact force sensing catheter

LV PMs (N = 59)	Non-CFS RF/CTII (N = 23)	CFS RF/ICE3D (N = 18)	CRYO/CTII (N = 18)	P
Catheter stability	6 (26%)	9 (50%)	18 (100%)	<0.0001
Pro-arrhythmia	18 (78%)	14 (78%)	0 (0%)	<0.0001
VEGM-QRS	32.4 ± 5.6 ms	33.2 ± 4.7 ms	30.2 ± 12.4 ms	1
PMAP score	22 (IQR 22-24)	22 (IQR 22-24)	22 (IQR 22-24)	0.7
Effective lesion location				
I- PM Apex	2 (9%)	1 (6%)	2 (11%)	0.1
II- PM Body	2 (9%)	8 (44%)	5 (28%)	0.1
III- PM Base	19 (82%)	9 (50%)	11 (61%)	0.1
CRYO dose (seg.)	N/A	N/A	766.7 ± 321.8	N/A
RF Dose (seg.)	361.6 ± 182.3	915 ± 653.1	N/A	N/A
Success	19 (83%)	18 (100%)	18 (100%)	0.03
Patients (N = 53)				
	Non-CFS RF/CTII (N = 23)	CFS RF/ICE3D (N = 14)	CRYO/CTII (N = 16)	P
Procedure duration	139 ± 39.7 min	164.5 ± 58 min	131.3 ± 26.2 min	0.3
Fluoroscopy time	14.2 ± 4.6 min	6.2 ± 1.5 min	10.7 ± 4.2 min	<0.0001
Transeptal access	10 (44%)	8 (57%)	16 (100%)	0.001
Minor complications	0	2 (12%)	0	0.1
Major Complications	1 (4%)	0	0	0.8
Prior ablation	0	2 (14%)	0	0.06
Circumferential	0	3 (21%)	2 (13%)	0.08
Focal	23 (100%)	12 (86%)	14 (88%)	0.2
Recurrence	11 (48%)	1 (7%)	3 (19%)	0.0172
FUP time (Mo)	12 ± 10	15 ± 18	13 ± 7.5	0.5307





Interval	0	4	4	8	8	12	12	16	16	20	20	24
CFS-ICE3D	14		6		4		2		0		0	
Non-CFS	20		14		9		6		3		1	
Cryo	17		16		13		8		3		1	

FIGURE 4 Patients free from ventricular arrhythmias after catheter ablation





Tip or Base?

- Successful ablation site was located on
 - Tip 67%
 - Mid 19%
 - Base 14%





Post procedure TTE & ablation efficacy





Practical aspect of ablation for PM PVC

- ICE is necessary!
- Consideration anatomy
- If unsuccessful, change the access route
 - Retrograde vs. transseptal
- High power may be required without good contact
 - 30 to 70W, impedance drops upto 8 to 10 Ω
 - Be careful at the base
 - Consider rapid pacing to suppress cardiac motion
- Cryoablation to improve stability can help.



Summary

- PVC from papillary m have specific characteristics.
- Ablation may be challenging
- The recurrence risk is higher than for other forms of idiopathic VT
- Minimize sedation till PVCs are seen and mapped
- ICE is very helpful for defining anatomy and monitoring catheter-tissue contact
- Cryo-ablation may prove better than RF energy, but larger studies are need for comparison


Thank you.

dongguk
UNIVERSITY


The logo of Dongguk University, featuring a stylized sunburst or flower-like shape with multiple petals in shades of yellow, orange, and red, centered around a dark circular core.

Role of Papillary Muscle in the Generation and Maintenance of Reentry During Ventricular Tachycardia and Fibrillation in Isolated Swine Right Ventricle


Young-Hoon Kim, MD; Fagen Xie, PhD; Masaaki Yashima, MD; Tsu-Juey Wu, MD;
 Miguel Valderrábano, MD; Moon-Hyoung Lee, MD; Toshihiko Ohara, MD; Olga Voroshilovsky, MS;
 Rahul N. Doshi, MD; Michael C. Fishbein, MD; Zhilin Qu, PhD; Alan Garfinkel, PhD;
 James N. Weiss, MD; Hrayr S. Karagueuzian, PhD; Peng-Sheng Chen, MD



F



G



Ventricular Fibrillation from PM

Ventricular Fibrillation Triggered by PVCs from Papillary

RESULTS - ECG presentation

RESULTS: PLPs potentials

PAT
M

Six patient
nonischemic

In 2 patient
muscle; in
papillary

PVCs from
posterior
PM rev
bundle
block (I
morpho
(positiv
transiti
V5 and
superic

PVCs were
posterior
PVCs occur
remain
phenylep
Earliest a
the ablat
intracard
was $42 \pm$

Pace map
match with
all patient
An ICE gu
was performed
activation
mapping.

Purkinje-like potentials (PLPs) preceding the PVC were found in 4 out of 6 patients.

PLPs were noted to precede the PVC potential arising from the RV posterolateral PM, in 3 out of 4 patients

PLPs were present in the septal and mitral annular endocardial scar of the patient with NICM.

The septal scar extended to the medial border of the PM in this patient and these 2 areas were targeted for ablation with consolidating lesions.





PM VTs and mitral valve prolaps

- 7% of patients with SCD had MVP
- PVCs from PM may act as trigger VF in MVP
- Possible mechanism
 - Mechanical stretch, elongated chordae → fibrosis → conduction delay and micro-reentry
 - MRI-LGE – inferobasal wall fibrosis
- MVP not seem to impair successful PVC ablation

